IRB Study Number 22-115
Status Recruiting
Phase Phase 2
Institute Neurological Institute
Description
ARGX-117-2002 is a randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and tolerability, efficacy, PK, PD, and immunogenicity of 2 dose regimens of ARGX-117 in adults with MMN.
Inclusion Criteria
- Males or females at least 18 years of age with probable or definite MMN at screening.
Exclusion Criteria
- Individuals under the age of 18
